Home › Head and Neck Squamous Cell Carcinoma › Tennessee › Knoxville
Head and Neck Squamous Cell Carcinoma clinical trials in Knoxville, TN
4 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Knoxville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RecruitingPhase 3
- Tennessee Cancer Specialists, Knoxville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- University of Tennessee Medical Center, Knoxville
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
- University of Tennessee - Knoxville, Knoxville
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
Recruiting
- Thompson Proton Center, Knoxville
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- New York City, NY39 studies
- Nashville, TN39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Chicago, IL26 studies
- Philadelphia, PA26 studies
- Atlanta, GA24 studies
- San Antonio, TX22 studies
- New Haven, CT22 studies
Other studies in Knoxville
- Non-Small Cell Lung Cancer14 studies
- Obesity10 studies
- Lung Cancer10 studies
- Breast Cancer9 studies
- Cancer (all types)8 studies
- Overweight7 studies
- Heart Failure7 studies
- Metastatic Cancer7 studies
- Cardiovascular Disease6 studies
- Melanoma5 studies
- Type 2 Diabetes5 studies
- High Blood Pressure5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.